What is HC Wainwright's Estimate for CRDF FY2025 Earnings?
HC Wainwright has increased its FY2025 earnings estimate for Cardiff Oncology to ($0.76) per share, up from ($0.85). The firm maintains a "Buy" rating with a $10.00 target price. Cardiff Oncology's stock is currently rated as "Moderate Buy" with a consensus target price of $10.63. The company reported Q3 earnings of ($0.17) per share, beating estimates by $0.03.
Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Equities researchers at HC Wainwright upped their FY2025 earnings estimates for Cardiff Oncology in a note issued to investors on Wednesday, November 12th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($0.76) per share for the year, up from their previous forecast of ($0.85). HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Cardiff Oncology's current full-year earnings is ($0.99) per share. HC Wainwright also issued estimates for Cardiff Oncology's Q4 2025 earnings at ($0.18) EPS, Q1 2026 earnings at ($0.16) EPS, Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.16) EPS and FY2026 earnings at ($0.64) EPS.
Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.20) by $0.03. The business had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.12 million. Cardiff Oncology had a negative return on equity of 77.21% and a negative net margin of 10,064.27%.
Get Cardiff Oncology alerts:
Separately, Weiss Ratings restated a "sell (d-)" rating on shares of Cardiff Oncology in a research report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Cardiff Oncology presently has an average rating of "Moderate Buy" and a consensus target price of $10.63.
View Our Latest Stock Analysis on CRDF
Cardiff Oncology Stock Up 0.7%
Cardiff Oncology stock traded up $0.02 during midday trading on Friday, reaching $2.17. The stock had a trading volume of 329,676 shares, compared to its average volume of 1,276,984. Cardiff Oncology has a 52-week low of $1.90 and a 52-week high of $5.64. The firm has a market cap of $145.83 million, a price-to-earnings ratio of -2.74 and a beta of 1.68. The company has a fifty day moving average of $2.18 and a 200 day moving average of $2.77.
Hedge Funds Weigh In On Cardiff Oncology
Large investors have recently added to or reduced their stakes in the business. AlphaCore Capital LLC grew its holdings in Cardiff Oncology by 8.2% in the 3rd quarter. AlphaCore Capital LLC now owns 109,926 shares of the company's stock worth $226,000 after buying an additional 8,351 shares in the last quarter. Readystate Asset Management LP acquired a new stake in shares of Cardiff Oncology during the third quarter worth $43,000. Post Resch Tallon Group Inc. purchased a new stake in Cardiff Oncology during the third quarter valued at about $46,000. HB Wealth Management LLC purchased a new position in shares of Cardiff Oncology in the third quarter worth approximately $148,000. Finally, Jeppson Wealth Management LLC purchased a new stake in shares of Cardiff Oncology in the 3rd quarter valued at approximately $25,000. 16.29% of the stock is currently owned by hedge funds and other institutional investors.
About Cardiff Oncology
(Get Free Report)Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.
Recommended Stories
- Five stocks we like better than Cardiff Oncology
- Canadian Penny Stocks: Can They Make You Rich?
- CRWD Stock Hits Key Inflection Point Ahead of Earnings
- Using the MarketBeat Dividend Tax Calculator
- Rigetti’s Q3 Miss Reveals Quantum Funding and Timing Pressures
- How to Invest in Insurance Companies: A Guide
- Monolithic Power Surges in 2025—Time to Buy or Hold?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Cardiff Oncology Right Now?
Before you consider Cardiff Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiff Oncology wasn't on the list.
While Cardiff Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
